{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:05:25Z","timestamp":1784804725359,"version":"3.55.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["USAMRAA W81XWH-21-1-0426"],"award-info":[{"award-number":["USAMRAA W81XWH-21-1-0426"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-21-1-0424"],"award-info":[{"award-number":["W81XWH-21-1-0424"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institute of Health Research","doi-asserted-by":"crossref","award":["451090"],"award-info":[{"award-number":["451090"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40291-026-00848-3","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:45:34Z","timestamp":1776408334000},"page":"545-560","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic Strategies Targeting the Molecular Pathogenesis of Myotonic Dystrophy Type 1: Current Status and Future Directions"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9500-2839","authenticated-orcid":false,"given":"Mohamed","family":"Chahine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamsi Krishna Murthy","family":"Ginjupalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Jauvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Boutjdir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"848_CR1","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/BF01649715","volume":"39","author":"H Steinert","year":"1909","unstructured":"Steinert H. Myopathologische Beitr\u00e4ge 1. \u00dcber das klinische und anatomische Bild des Muskelschwunds der Myotoniker. Dtsch Z Nervenheilkd. 1909;39:168\u201373.","journal-title":"Dtsch Z Nervenheilkd"},{"issue":"5","key":"848_CR2","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1086\/383590","volume":"74","author":"LP Ranum","year":"2004","unstructured":"Ranum LP, Day JW. Myotonic dystrophy: RNA pathogenesis comes into focus. Am J Hum Genet. 2004;74(5):793\u2013804.","journal-title":"Am J Hum Genet"},{"issue":"11","key":"848_CR3","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.nmd.2012.05.017","volume":"22","author":"J Mathieu","year":"2012","unstructured":"Mathieu J, Prevost C. Epidemiological surveillance of Myotonic dystrophy type 1: a 25-year population-based study. Neuromuscul Disord. 2012;22(11):974\u20139.","journal-title":"Neuromuscul Disord"},{"issue":"10","key":"848_CR4","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.neurol.2016.08.003","volume":"172","author":"M De Antonio","year":"2016","unstructured":"De Antonio M, Dogan C, Hamroun D, Mati M, Zerrouki S, Eymard B, et al. Unravelling the Myotonic dystrophy type 1 clinical spectrum: a systematic registry-based study with implications for disease classification. Rev Neurol (Paris). 2016;172(10):572\u201380.","journal-title":"Rev Neurol (Paris)"},{"key":"848_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00303","volume":"9","author":"S Wenninger","year":"2018","unstructured":"Wenninger S, Montagnese F, Schoser B. Core clinical phenotypes in Myotonic dystrophies. Front Neurol. 2018;9:303.","journal-title":"Front Neurol"},{"issue":"2","key":"848_CR6","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/0092-8674(92)90418-C","volume":"69","author":"JD Brook","year":"1992","unstructured":"Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3\u2032 end of a transcript encoding a protein kinase family member. Cell. 1992;69(2):385.","journal-title":"Cell"},{"issue":"2","key":"848_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/BF00887824","volume":"242","author":"A Jaspert","year":"1995","unstructured":"Jaspert A, Fahsold R, Grehl H, Claus D. Myotonic dystrophy: correlation of clinical symptoms with the size of the CTG trinucleotide repeat. J Neurol. 1995;242(2):99\u2013104.","journal-title":"J Neurol"},{"issue":"3","key":"848_CR8","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/ng0796-316","volume":"13","author":"G Jansen","year":"1996","unstructured":"Jansen G, Groenen PJ, Bachner D, Jap PH, Coerwinkel M, Oerlemans F, et al. Abnormal myotonic dystrophy protein kinase levels produce only mild myopathy in mice. Nat Genet. 1996;13(3):316\u201324.","journal-title":"Nat Genet"},{"issue":"3","key":"848_CR9","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/ng0796-325","volume":"13","author":"S Reddy","year":"1996","unstructured":"Reddy S, Smith DB, Rich MM, Leferovich JM, Reilly P, Davis BM, et al. Mice lacking the Myotonic dystrophy protein kinase develop a late onset progressive myopathy. Nat Genet. 1996;13(3):325\u201335.","journal-title":"Nat Genet"},{"key":"848_CR10","doi-asserted-by":"crossref","unstructured":"Chahine M, George AL Jr. Myotonic dystrophy kinase modulates skeletal muscle but not cardiac voltage-gated sodium channels. FEBS Lett. 1997;412(3):621\u20134.","DOI":"10.1016\/S0014-5793(97)00869-7"},{"issue":"17","key":"848_CR11","doi-asserted-by":"publisher","first-page":"10873","DOI":"10.1093\/nar\/gku767","volume":"42","author":"P Konieczny","year":"2014","unstructured":"Konieczny P, Stepniak-Konieczna E, Sobczak K. MBNL proteins and their target RNAs, interaction and splicing regulation. Nucleic Acids Res. 2014;42(17):10873\u201387.","journal-title":"Nucleic Acids Res"},{"issue":"13","key":"848_CR12","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1093\/hmg\/ddl132","volume":"15","author":"X Lin","year":"2006","unstructured":"Lin X, Miller JW, Mankodi A, Kanadia RN, Yuan Y, Moxley RT, et al. Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum Mol Genet. 2006;15(13):2087\u201397.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"848_CR13","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/wrna.107","volume":"3","author":"T Dasgupta","year":"2012","unstructured":"Dasgupta T, Ladd AN. The importance of CELF control: molecular and biological roles of the CUG-BP, Elav-like family of RNA-binding proteins. WIREs RNA. 2012;3(1):104\u201321.","journal-title":"WIREs RNA"},{"issue":"1","key":"848_CR14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.molcel.2007.07.027","volume":"28","author":"NM Kuyumcu-Martinez","year":"2007","unstructured":"Kuyumcu-Martinez NM, Wang GS, Cooper TA. Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol Cell. 2007;28(1):68\u201378.","journal-title":"Mol Cell"},{"issue":"10","key":"848_CR15","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1093\/hmg\/ddaa095","volume":"29","author":"DC Cox","year":"2020","unstructured":"Cox DC, Guan X, Xia Z, Cooper TA. Increased nuclear but not cytoplasmic activities of CELF1 protein leads to muscle wasting. Hum Mol Genet. 2020;29(10):1729\u201344.","journal-title":"Hum Mol Genet"},{"issue":"17","key":"848_CR16","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.1093\/emboj\/19.17.4439","volume":"19","author":"JW Miller","year":"2000","unstructured":"Miller JW, Urbinati CR, Teng-Umnuay P, Stenberg MG, Byrne BJ, Thornton CA, et al. Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. EMBO J. 2000;19(17):4439\u201348.","journal-title":"EMBO J"},{"issue":"8","key":"848_CR17","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.molmed.2012.06.006","volume":"18","author":"RK Singh","year":"2012","unstructured":"Singh RK, Cooper TA. Pre-mRNA splicing in disease and therapeutics. Trends Mol Med. 2012;18(8):472\u201382.","journal-title":"Trends Mol Med"},{"issue":"22","key":"848_CR18","doi-asserted-by":"publisher","first-page":"10992","DOI":"10.3390\/ijms262210992","volume":"26","author":"VKM Ginjupalli","year":"2025","unstructured":"Ginjupalli VKM, Reisqs JB, Cupelli M, Chahine M, Boutjdir M. Cardiac involvement in nyotonic dystrophy type 1: mechanisms, clinical perspectives, and emerging therapeutic strategies. Int J Mol Sci. 2025;26(22):10992.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"848_CR19","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1038\/ng1857","volume":"38","author":"MS Mahadevan","year":"2006","unstructured":"Mahadevan MS, Yadava RS, Yu Q, Balijepalli S, Frenzel-McCardell CD, Bourne TD, et al. Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy. Nat Genet. 2006;38(9):1066\u201370.","journal-title":"Nat Genet"},{"issue":"180","key":"848_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117562","volume":"17","author":"M Cupelli","year":"2024","unstructured":"Cupelli M, Ginjupalli VKM, Reisqs JB, Sleiman Y, El-Sherif N, Gourdon G, et al. Calcium handling abnormalities increase arrhythmia susceptibility in DMSXL myotonic dystrophy type 1 mice. Biomed Pharmacother. 2024;17(180):117562.","journal-title":"Biomed Pharmacother"},{"key":"848_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2023.1257682","volume":"14","author":"VKM Ginjupalli","year":"2023","unstructured":"Ginjupalli VKM, Cupelli M, Reisqs JB, Sleiman Y, El-Sherif N, Gourdon G, et al. Electrophysiological basis of cardiac arrhythmia in a mouse model of myotonic dystrophy type 1. Front Physiol. 2023;14:1257682.","journal-title":"Front Physiol"},{"issue":"4","key":"848_CR22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nrg2748","volume":"11","author":"AR La Spada","year":"2010","unstructured":"La Spada AR, Taylor JP. Repeat expansion disease: progress and puzzles in disease pathogenesis. Nat Rev Genet. 2010;11(4):247\u201358.","journal-title":"Nat Rev Genet"},{"issue":"11","key":"848_CR23","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/nrg2828","volume":"11","author":"CT McMurray","year":"2010","unstructured":"McMurray CT. Mechanisms of trinucleotide repeat instability during human development. Nat Rev Genet. 2010;11(11):786\u201399.","journal-title":"Nat Rev Genet"},{"issue":"7","key":"848_CR24","doi-asserted-by":"publisher","first-page":"13272","DOI":"10.1038\/ncomms13272","volume":"9","author":"C Cinesi","year":"2016","unstructured":"Cinesi C, Aeschbach L, Yang B, Dion V. Contracting CAG\/CTG repeats using the CRISPR-Cas9 nickase. Nat Commun. 2016;9(7):13272.","journal-title":"Nat Commun"},{"issue":"1","key":"848_CR25","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ymthe.2016.10.014","volume":"25","author":"EL van Agtmaal","year":"2017","unstructured":"van Agtmaal EL, Andr\u00e9 LM, Willemse M, Cumming SA, van Kessel IDG, van den Broek W, et al. CRISPR\/Cas9-induced (CTG\u22c5CAG)(n) repeat instability in the myotonic dystrophy type 1 locus: implications for therapeutic genome editing. Mol Ther. 2017;25(1):24\u201343.","journal-title":"Mol Ther"},{"issue":"27","key":"848_CR26","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.omtn.2021.11.024","volume":"8","author":"B Cardinali","year":"2022","unstructured":"Cardinali B, Provenzano C, Izzo M, Voellenkle C, Battistini J, Strimpakos G, et al. Time-controlled and muscle-specific CRISPR\/Cas9-mediated deletion of CTG-repeat expansion in the DMPK gene. Mol Ther Nucleic Acids. 2022;8(27):184\u201399.","journal-title":"Mol Ther Nucleic Acids."},{"issue":"9","key":"848_CR27","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.omtn.2017.10.006","volume":"15","author":"C Provenzano","year":"2017","unstructured":"Provenzano C, Cappella M, Valaperta R, Cardani R, Meola G, Martelli F, et al. CRISPR\/Cas9-mediated deletion of CTG expansions recovers normal phenotype in myogenic cells derived from myotonic dystrophy 1 patients. Mol Ther Nucleic Acids. 2017;15(9):337\u201348.","journal-title":"Mol Ther Nucleic Acids."},{"issue":"8","key":"848_CR28","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.ymthe.2019.05.021","volume":"27","author":"M Lo Scrudato","year":"2019","unstructured":"Lo Scrudato M, Poulard K, Sourd C, Tom\u00e9 S, Klein AF, Corre G, et al. Genome editing of expanded CTG repeats within the human DMPK gene reduces nuclear RNA foci in the muscle of DM1 mice. Mol Ther. 2019;27(8):1372\u201388.","journal-title":"Mol Ther"},{"issue":"23","key":"848_CR29","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1093\/hmg\/10.23.2717","volume":"10","author":"H Seznec","year":"2001","unstructured":"Seznec H, Agbulut O, Sergeant N, Savouret C, Ghestem A, Tabti N, et al. Mice transgenic for the human myotonic dystrophy region with expanded CTG repeats display muscular and brain abnormalities. Hum Mol Genet. 2001;10(23):2717\u201326.","journal-title":"Hum Mol Genet"},{"issue":"8","key":"848_CR30","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1093\/hmg\/9.8.1185","volume":"9","author":"H Seznec","year":"2000","unstructured":"Seznec H, Lia-Baldini AS, Duros C, Fouquet C, Lacroix C, Hofmann-Radvanyi H, et al. Transgenic mice carrying large human genomic sequences with expanded CTG repeat mimic closely the DM CTG repeat intergenerational and somatic instability. Hum Mol Genet. 2000;9(8):1185\u201394.","journal-title":"Hum Mol Genet"},{"issue":"2","key":"848_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70227","volume":"15","author":"M Izzo","year":"2025","unstructured":"Izzo M, Battistini J, Golini E, Voellenkle C, Provenzano C, Orsini T, et al. Muscle-specific gene editing improves molecular and phenotypic defects in a mouse model of myotonic dystrophy type 1. Clin Transl Med. 2025;15(2):e70227.","journal-title":"Clin Transl Med"},{"issue":"4","key":"848_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/narmme\/ugae013","volume":"1","author":"M Larin","year":"2024","unstructured":"Larin M, Gidney F, Aeschbach L, Heraty L, Randall EL, Heuchan AER, et al. Cas9 nickase-mediated contractions of CAG\/CTG repeats are transcription-dependent and replication-independent. NAR Mol Med. 2024;1(4):ugae013.","journal-title":"NAR Mol Med"},{"issue":"19","key":"848_CR33","doi-asserted-by":"publisher","first-page":"5463","DOI":"10.1093\/nar\/gkg767","volume":"31","author":"A Jasinska","year":"2003","unstructured":"Jasinska A, Michlewski G, de Mezer M, Sobczak K, Kozlowski P, Napierala M, et al. Structures of trinucleotide repeats in human transcripts and their functional implications. Nucleic Acids Res. 2003;31(19):5463\u20138.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"848_CR34","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41551-020-00607-7","volume":"5","author":"R Batra","year":"2021","unstructured":"Batra R, Nelles DA, Roth DM, Krach F, Nutter CA, Tadokoro T, et al. The sustained expression of Cas9 targeting toxic RNAs reverses disease phenotypes in mouse models of myotonic dystrophy type 1. Nat Biomed Eng. 2021;5(2):157\u201368.","journal-title":"Nat Biomed Eng."},{"issue":"16","key":"848_CR35","doi-asserted-by":"publisher","first-page":"8275","DOI":"10.1093\/nar\/gky548","volume":"46","author":"S Dastidar","year":"2018","unstructured":"Dastidar S, Ardui S, Singh K, Majumdar D, Nair N, Fu Y, et al. Efficient CRISPR\/Cas9-mediated editing of trinucleotide repeat expansion in myotonic dystrophy patient-derived iPS and myogenic cells. Nucleic Acids Res. 2018;46(16):8275\u201398.","journal-title":"Nucleic Acids Res"},{"issue":"21","key":"848_CR36","doi-asserted-by":"publisher","first-page":"13359","DOI":"10.3390\/ijms232113359","volume":"23","author":"T De Serres-B\u00e9rard","year":"2022","unstructured":"De Serres-B\u00e9rard T, Ait Benichou S, Jauvin D, Boutjdir M, Puymirat J, Chahine M. Recent progress and challenges in the development of antisense therapies for myotonic dystrophy type 1. Int J Mol Sci. 2022;23(21):13359.","journal-title":"Int J Mol Sci"},{"issue":"15-16","key":"848_CR37","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1089\/hum.2022.069","volume":"33","author":"S Ait Benichou","year":"2022","unstructured":"Ait Benichou S, Jauvin D, De Serres-B\u00e9rard T, Bennett F, Rigo F, Gourdon G, et al. Enhanced delivery of ligand-conjugated antisense oligonucleotides (C16-HA-ASO) targeting dystrophia myotonica protein kinase transcripts for the treatment of myotonic dystrophy type 1. Hum Gene Ther. 2022;33(15\u201316):810\u201320.","journal-title":"Hum Gene Ther"},{"issue":"11","key":"848_CR38","doi-asserted-by":"publisher","first-page":"4739","DOI":"10.1172\/JCI128205","volume":"129","author":"AF Klein","year":"2019","unstructured":"Klein AF, Varela MA, Arandel L, Holland A, Naouar N, Arzumanov A, et al. Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice. J Clin Investig. 2019;129(11):4739\u201344.","journal-title":"J Clin Investig"},{"issue":"6669","key":"848_CR39","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/35888","volume":"391","author":"A Fire","year":"1998","unstructured":"Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806\u201311.","journal-title":"Nature"},{"key":"848_CR40","doi-asserted-by":"crossref","unstructured":"Johnson NE, Ta L-J, Hame JI, Day JW, Statland JM, Soltanzadeh P, et al. An antibody\u2013oligonucleotide conjugate for myotonic dystrophy type 1. N Engl J Med. 2026;394(8):763\u2013772.","DOI":"10.1056\/NEJMoa2407326"},{"issue":"12","key":"848_CR41","doi-asserted-by":"publisher","first-page":"6350","DOI":"10.1016\/j.ymthe.2025.08.050","volume":"33","author":"GS Tomassy","year":"2025","unstructured":"Tomassy GS, Fan W, Cao S, Luo Z, Magli A, Zhang T, et al. Development of an AAV-delivered microRNA gene therapy for myotonic dystrophy type 1. Mol Ther. 2025;33(12):6350\u20132.","journal-title":"Mol Ther"},{"issue":"2","key":"848_CR42","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41551-021-00838-2","volume":"6","author":"L Arandel","year":"2022","unstructured":"Arandel L, Matloka M, Klein AF, Rau F, Sureau A, Ney M, et al. Reversal of RNA toxicity in myotonic dystrophy via a decoy RNA-binding protein with high affinity for expanded CUG repeats. Nat Biomed Eng. 2022;6(2):207\u201320.","journal-title":"Nat Biomed Eng"},{"issue":"4","key":"848_CR43","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.3390\/ijms24043794","volume":"24","author":"N Neault","year":"2023","unstructured":"Neault N, Ravel-Chapuis A, Baird SD, Lunde JA, Poirier M, Staykov E, et al. Vorinostat improves myotonic dystrophy type 1 splicing abnormalities in DM1 muscle cell lines and skeletal muscle from a DM1 mouse model. Int J Mol Sci. 2023;24(4):3794.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"848_CR44","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1093\/brain\/awy231","volume":"141","author":"G Bassez","year":"2018","unstructured":"Bassez G, Audureau E, Hogrel JY, Arrouasse R, Baghdoyan S, Bhugaloo H, et al. Improved mobility with metformin in patients with myotonic dystrophy type 1: a randomized controlled trial. Brain. 2018;141(10):2855\u201365.","journal-title":"Brain"},{"key":"848_CR45","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.pediatrneurol.2020.08.001","volume":"112","author":"J Horrigan","year":"2020","unstructured":"Horrigan J, Gomes TB, Snape M, Nikolenko N, McMorn A, Evans S, et al. A phase 2 study of AMO-02 (tideglusib) in congenital and childhood-onset myotonic dystrophy type 1 (DM1). Pediatr Neurol. 2020;112:84\u201393.","journal-title":"Pediatr Neurol"},{"key":"848_CR46","doi-asserted-by":"publisher","unstructured":"Mishra SK, Hicks SM, Frias JA, Vangaveti S, Nakamori M, Cleary JD, et al. Quercetin selectively reduces expanded repeat RNA levels in models of myotonic dystrophy. bioRxiv [Preprint]. 2023. https:\/\/doi.org\/10.1101\/2023.02.02.526846.","DOI":"10.1101\/2023.02.02.526846"},{"key":"848_CR47","doi-asserted-by":"publisher","DOI":"10.1523\/ENEURO.0218-22.2022","author":"KS Edokpolor","year":"2022","unstructured":"Edokpolor KS, Banerjee A, McEachin ZT, Gu J, Kosti A, Arboleda JD, et al. Altered behavioral responses show GABA sensitivity in muscleblind-like 2-deficient mice: implications for CNS symptoms in myotonic dystrophy. eNeuro. 2022. https:\/\/doi.org\/10.1523\/ENEURO.0218-22.2022.","journal-title":"eNeuro"},{"issue":"11","key":"848_CR48","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1016\/j.ymthe.2018.09.003","volume":"26","author":"Y Wang","year":"2018","unstructured":"Wang Y, Hao L, Wang H, Santostefano K, Thapa A, Cleary J, et al. Therapeutic genome editing for myotonic dystrophy type 1 using CRISPR\/Cas9. Mol Ther. 2018;26(11):2617\u201330.","journal-title":"Mol Ther"},{"issue":"31","key":"848_CR49","doi-asserted-by":"publisher","first-page":"11748","DOI":"10.1073\/pnas.0604970103","volume":"103","author":"RN Kanadia","year":"2006","unstructured":"Kanadia RN, Shin J, Yuan Y, Beattie SG, Wheeler TM, Thornton CA, et al. Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. Proc Natl Acad Sci USA. 2006;103(31):11748\u201353.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"848_CR50","doi-asserted-by":"publisher","DOI":"10.1172\/JCI186416","volume":"135","author":"RC Hu","year":"2025","unstructured":"Hu RC, Zhang Y, Nitschke L, Johnson SJ, Hurley AE, Lagor WR, et al. MBNL overexpression rescues cardiac phenotypes in a myotonic dystrophy type 1 heart mouse model. J Clin Investig. 2025;135(7):e186416.","journal-title":"J Clin Investig"},{"key":"848_CR51","doi-asserted-by":"crossref","unstructured":"Musia\u0142a-Kierklo N, Plewka P, Jasiok A, St\u0119pniak-Konieczna E. Promoter-targeted small RNA duplexes increase MBNL1 transcription and mitigate myotonic dystrophy-associated spliceopathy. Nucleic Acids Res. 2025;53(15):gkaf756.","DOI":"10.1093\/nar\/gkaf756"},{"issue":"12","key":"848_CR52","first-page":"3952","volume":"117","author":"TM Wheeler","year":"2007","unstructured":"Wheeler TM, Lueck JD, Swanson MS, Dirksen RT, Thornton CA. Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J Clin Invest. 2007;117(12):3952\u20137.","journal-title":"J Clin Invest"},{"issue":"7","key":"848_CR53","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.omtn.2017.05.007","volume":"16","author":"D Jauvin","year":"2017","unstructured":"Jauvin D, Chretien J, Pandey SK, Martineau L, Revillod L, Bassez G, et al. Targeting DMPK with antisense oligonucleotide improves muscle strength in myotonic dystrophy type 1 mice. Mol Ther Nucleic Acids. 2017;16(7):465\u201374.","journal-title":"Mol Ther Nucleic Acids."},{"issue":"11","key":"848_CR54","doi-asserted-by":"publisher","first-page":"4221","DOI":"10.1073\/pnas.1117019109","volume":"109","author":"JE Lee","year":"2012","unstructured":"Lee JE, Bennett CF, Cooper TA. RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1. Proc Natl Acad Sci USA. 2012;109(11):4221\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"22","key":"848_CR55","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1093\/hmg\/ddaf153","volume":"34","author":"EC Kuijper","year":"2025","unstructured":"Kuijper EC, van der Graaf L, Pepers BA, Guimaraes Ramos M, Korhorn S, Toonen LJA, et al. Determining off-target effects of splice-switching antisense oligonucleotides using short read RNAseq in neuronally differentiated human induced pluripotent stem cells. Hum Mol Genet. 2025;34(22):1912\u201325.","journal-title":"Hum Mol Genet"},{"issue":"3","key":"848_CR56","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S1474-4422(23)00001-7","volume":"22","author":"CA Thornton","year":"2023","unstructured":"Thornton CA, Moxley RT 3rd, Eichinger K, Heatwole C, Mignon L, Arnold WD, et al. Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1\/2a trial. Lancet Neurol. 2023;22(3):218\u201328.","journal-title":"Lancet Neurol"},{"issue":"12","key":"848_CR57","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41434-022-00316-7","volume":"29","author":"S Ait Benichou","year":"2022","unstructured":"Ait Benichou S, Jauvin D, De Serres-B\u00e9rard T, Pierre M, Ling KK, Bennett CF, et al. Antisense oligonucleotides as a potential treatment for brain deficits observed in myotonic dystrophy type 1. Gene Ther. 2022;29(12):698\u2013709.","journal-title":"Gene Ther"},{"issue":"12","key":"848_CR58","doi-asserted-by":"publisher","first-page":"6029","DOI":"10.1093\/nar\/gkz354","volume":"47","author":"TP Prakash","year":"2019","unstructured":"Prakash TP, Mullick AE, Lee RG, Yu J, Yeh ST, Low A, et al. Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle. Nucleic Acids Res. 2019;47(12):6029\u201344.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"848_CR59","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.3390\/ijms24032697","volume":"24","author":"J Stoodley","year":"2023","unstructured":"Stoodley J, Vallejo-Bedia F, Seone-Miraz D, Debasa-Mouce M, Wood MJA, Varela MA. Application of antisense conjugates for the treatment of myotonic dystrophy type 1. Int J Mol Sci. 2023;24(3):2697.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"848_CR60","doi-asserted-by":"publisher","first-page":"4382","DOI":"10.1093\/nar\/gkaa164","volume":"48","author":"AE Chappell","year":"2020","unstructured":"Chappell AE, Gaus HJ, Berdeja A, Gupta R, Jo M, Prakash TP, et al. Mechanisms of palmitic acid-conjugated antisense oligonucleotide distribution in mice. Nucleic Acids Res. 2020;48(8):4382\u201395.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"848_CR61","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/nar\/gkab1199","volume":"50","author":"K Relizani","year":"2022","unstructured":"Relizani K, Echevarr\u00eda L, Zarrouki F, Gastaldi C, Dambrune C, Aupy P, et al. Palmitic acid conjugation enhances potency of tricyclo-DNA splice switching oligonucleotides. Nucleic Acids Res. 2022;50(1):17\u201334.","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"848_CR62","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1093\/nar\/gkad415","volume":"51","author":"B Malecova","year":"2023","unstructured":"Malecova B, Burke RS, Cochran M, Hood MD, Johns R, Kovach PR, et al. Targeted tissue delivery of RNA therapeutics using antibody-oligonucleotide conjugates (AOCs). Nucleic Acids Res. 2023;51(12):5901\u201310.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"848_CR63","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s43856-025-00733-w","volume":"5","author":"T Weeden","year":"2025","unstructured":"Weeden T, Picariello T, Quinn B, Spring S, Shen PY, Qiu Q, et al. FORCE platform overcomes barriers of oligonucleotide delivery to muscle and corrects myotonic dystrophy features in preclinical models. Commun Med (Lond). 2025;5(1):22.","journal-title":"Commun Med (Lond)."},{"issue":"11","key":"848_CR64","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.1172\/JCI131933","volume":"129","author":"EM McNally","year":"2019","unstructured":"McNally EM, Leverson BD. Better living through peptide-conjugated chemistry: next-generation antisense oligonucleotides. J Clin Investig. 2019;129(11):4570\u20131.","journal-title":"J Clin Investig"},{"issue":"17","key":"848_CR65","doi-asserted-by":"publisher","first-page":"16949","DOI":"10.1074\/jbc.M501591200","volume":"280","author":"MA Langlois","year":"2005","unstructured":"Langlois MA, Boniface C, Wang G, Alluin J, Salvaterra PM, Puymirat J, et al. Cytoplasmic and nuclear retained DMPK mRNAs are targets for RNA interference in myotonic dystrophy cells. J Biol Chem. 2005;280(17):16949\u201354.","journal-title":"J Biol Chem"},{"issue":"2","key":"848_CR66","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/mt.2012.222","volume":"21","author":"K Sobczak","year":"2013","unstructured":"Sobczak K, Wheeler TM, Wang W, Thornton CA. RNA interference targeting CUG repeats in a mouse model of myotonic dystrophy. Mol Ther. 2013;21(2):380\u20137.","journal-title":"Mol Ther"},{"issue":"12","key":"848_CR67","doi-asserted-by":"publisher","first-page":"5933","DOI":"10.1016\/j.ymthe.2025.10.063","volume":"33","author":"M Chahine","year":"2025","unstructured":"Chahine M. AAV-mediated DMPK silencing: a defining moment in myotonic dystrophy type 1 therapeutics. Mol Ther. 2025;33(12):5933\u20135.","journal-title":"Mol Ther"},{"issue":"1","key":"848_CR68","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1038\/s41467-018-04892-4","volume":"9","author":"E Cerro-Herreros","year":"2018","unstructured":"Cerro-Herreros E, Sabater-Arcis M, Fernandez-Costa JM, Moreno N, Perez-Alonso M, Llamusi B, et al. miR-23b and miR-218 silencing increase muscleblind-like expression and alleviate myotonic dystrophy phenotypes in mammalian models. Nat Commun. 2018;9(1):2482.","journal-title":"Nat Commun"},{"issue":"4","key":"848_CR69","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.3390\/pharmaceutics15041118","volume":"15","author":"SJ Overby","year":"2023","unstructured":"Overby SJ, Cerro-Herreros E, Espinosa-Espinosa J, Gonz\u00e1lez-Mart\u00ednez I, Moreno N, Fern\u00e1ndez-Costa JM, et al. BlockmiR AONs as site-specific therapeutic MBNL modulation in myotonic dystrophy 2D and 3D muscle cells and HSALR mice. Pharmaceutics. 2023;15(4):1118.","journal-title":"Pharmaceutics"},{"issue":"1","key":"848_CR70","doi-asserted-by":"publisher","first-page":"19417","DOI":"10.1038\/s41598-021-98866-0","volume":"11","author":"A Rapisarda","year":"2021","unstructured":"Rapisarda A, Bargiela A, Llamusi B, Pont I, Estrada-Tejedor R, Garcia-Espa\u00f1a E, et al. Defined D-hexapeptides bind CUG repeats and rescue phenotypes of myotonic dystrophy myotubes in a Drosophila model of the disease. Sci Rep. 2021;11(1):19417.","journal-title":"Sci Rep"},{"key":"848_CR71","doi-asserted-by":"crossref","unstructured":"Imai T, Miyai M, Nemoto J, Tamai T, Ohta M, Yagi Y, et al. Pentatricopeptide repeat protein targeting CUG repeat RNA ameliorates RNA toxicity in a myotonic dystrophy type 1 mouse model. Sci Transl Med. 2025;17(794):eadq2005.","DOI":"10.1126\/scitranslmed.adq2005"},{"issue":"6","key":"848_CR72","doi-asserted-by":"publisher","first-page":"25317","DOI":"10.1038\/srep25317","volume":"29","author":"G Chen","year":"2016","unstructured":"Chen G, Masuda A, Konishi H, Ohkawara B, Ito M, Kinoshita M, et al. Phenylbutazone induces expression of MBNL1 and suppresses formation of MBNL1-CUG RNA foci in a mouse model of myotonic dystrophy. Sci Rep. 2016;29(6):25317.","journal-title":"Sci Rep"},{"issue":"1","key":"848_CR73","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/acn3.271","volume":"3","author":"M Nakamori","year":"2016","unstructured":"Nakamori M, Taylor K, Mochizuki H, Sobczak K, Takahashi MP. Oral administration of erythromycin decreases RNA toxicity in myotonic dystrophy. Ann Clin Transl Neurol. 2016;3(1):42\u201354.","journal-title":"Ann Clin Transl Neurol"},{"issue":"10","key":"848_CR74","doi-asserted-by":"publisher","first-page":"6591","DOI":"10.1093\/nar\/gku275","volume":"42","author":"JW Hoskins","year":"2014","unstructured":"Hoskins JW, Ofori LO, Chen CZ, Kumar A, Sobczak K, Nakamori M, et al. Lomofungin and dilomofungin: inhibitors of MBNL1-CUG RNA binding with distinct cellular effects. Nucleic Acids Res. 2014;42(10):6591\u2013602.","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"848_CR75","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/hmg\/ddt542","volume":"23","author":"A Ketley","year":"2014","unstructured":"Ketley A, Chen CZ, Li X, Arya S, Robinson TE, Granados-Riveron J, et al. High-content screening identifies small molecules that remove nuclear foci, affect MBNL distribution and CELF1 protein levels via a PKC-independent pathway in myotonic dystrophy cell lines. Hum Mol Genet. 2014;23(6):1551\u201362.","journal-title":"Hum Mol Genet"},{"issue":"4","key":"848_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2015.35","volume":"3","author":"D Laustriat","year":"2015","unstructured":"Laustriat D, Gide J, Barrault L, Chautard E, Benoit C, Auboeuf D, et al. In vitro and in vivo modulation of alternative splicing by the biguanide metformin. Mol Ther Nucleic Acids. 2015;3(4):e262.","journal-title":"Mol Ther Nucleic Acids."},{"issue":"21","key":"848_CR77","doi-asserted-by":"publisher","first-page":"e00155","DOI":"10.1128\/MCB.00155-19","volume":"39","author":"M Wang","year":"2019","unstructured":"Wang M, Weng WC, Stock L, Lindquist D, Martinez A, Gourdon G, et al. Correction of glycogen synthase kinase 3\u03b2 in myotonic dystrophy 1 reduces the mutant RNA and improves postnatal survival of DMSXL mice. Mol Cell Biol. 2019;39(21):e00155-e219.","journal-title":"Mol Cell Biol"},{"issue":"2","key":"848_CR78","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.1212\/WNL.0000000000011002","volume":"96","author":"C Heatwole","year":"2021","unstructured":"Heatwole C, Luebbe E, Rosero S, Eichinger K, Martens W, Hilbert J, et al. Mexiletine in myotonic dystrophy type 1: a randomized, double-blind, placebo-controlled trial. Neurology. 2021;96(2):e228\u201340.","journal-title":"Neurology"},{"issue":"3","key":"848_CR79","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/ana.25017","volume":"82","author":"AA Hawash","year":"2017","unstructured":"Hawash AA, Voss AA, Rich MM. Inhibiting persistent inward sodium currents prevents myotonia. Ann Neurol. 2017;82(3):385\u201395.","journal-title":"Ann Neurol"},{"key":"848_CR80","doi-asserted-by":"publisher","first-page":"1258318","DOI":"10.3389\/fphys.2023.1258318","volume":"14","author":"M Pierre","year":"2023","unstructured":"Pierre M, Djemai M, Chapotte-Baldacci CA, Pouliot V, Puymirat J, Boutjdir M, et al. Cardiac involvement in patient-specific induced pluripotent stem cells of myotonic dystrophy type 1: unveiling the impact of voltage-gated sodium channels. Front Physiol. 2023;14:1258318.","journal-title":"Front Physiol"},{"issue":"8","key":"848_CR81","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1038\/mt.2016.97","volume":"24","author":"Y Gao","year":"2016","unstructured":"Gao Y, Guo X, Santostefano K, Wang Y, Reid T, Zeng D, et al. Genome therapy of myotonic dystrophy type 1 iPS cells for development of autologous stem cell therapy. Mol Ther. 2016;24(8):1378\u201387.","journal-title":"Mol Ther"},{"issue":"1","key":"848_CR82","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41598-022-26614-z","volume":"13","author":"R Kawada","year":"2023","unstructured":"Kawada R, Jonouchi T, Kagita A, Sato M, Hotta A, Sakurai H. Establishment of quantitative and consistent in vitro skeletal muscle pathological models of myotonic dystrophy type 1 using patient-derived iPSCs. Sci Rep. 2023;13(1):94.","journal-title":"Sci Rep"},{"issue":"1","key":"848_CR83","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s13287-024-03913-y","volume":"15","author":"RHL Raaijmakers","year":"2024","unstructured":"Raaijmakers RHL, Ausems CRM, Willemse M, Cumming SA, van Engelen BGM, Monckton DG, et al. Ameliorated cellular hallmarks of myotonic dystrophy in hybrid myotubes from patient and unaffected donor cells. Stem Cell Res Ther. 2024;15(1):302.","journal-title":"Stem Cell Res Ther"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-026-00848-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-026-00848-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-026-00848-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T11:29:29Z","timestamp":1782818969000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-026-00848-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":83,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["848"],"URL":"https:\/\/doi.org\/10.1007\/s40291-026-00848-3","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"19 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by a US Department of Defense grant (USAMRAA W81XWH-21-1-0426) to Mohamed Chahine, a US Department of Defense award (W81XWH-21-1-0424) to Mohamed Boutjdir. This work was also supported by the Canadian Institutes of Health Research (451090).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Mohamed Chahine, Vamsi Krishna Murthy Ginjupalli, Dominic Jauvin, and Mohamed Boutjdir have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MC conceptualized the study. MC and MB acquired the funding and managed the project. MC supervised the project. MC wrote the original draft. MC, DJ, VKMG, and MB reviewed and edited the manuscript draft. All authors read and approved the final version of the manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}